Investor Alert




Covid Long-Haulers Fear for Their Future

  • Covid Long-Haulers Fear for Their Future Covid Long-Haulers Fear for Their Future 6:35
    WSJ Opinion: Hits and Misses of the Week WSJ Opinion: Hits and Misses of the Week 2:15
    The Science Behind How the Coronavirus Affects the Brain The Science Behind How the Coronavirus Affects the Brain 7:20
12:10 p.m. Today - MarketWatch.com
What will you call home when you’re older? The ultimate guide to housing in later lifeWill you age in place, live like the 'Golden Girls' or move in with family? Here's a guide to housing options for retirees, with resources to help find what's right for you.
10:10 a.m. Sept. 17, 2021 - By Teepa Snow
My friend has dementia, what can I do?5 ways to support a friend after a dementia diagnosis
3:01 p.m. Sept. 9, 2021 - Barrons.com
Biogen Stock Tumbled Because Its Alzheimer's Drug Rollout Isn't Going So Well The biotech giant says that the launch of controversial Alzheimer's disease drug, Aduhelm, faces some 'near-term challenges.'
12:04 p.m. Sept. 9, 2021 - By CD Moriarty
Your financial power of attorney may fail you when you need it mostThe legal documents --- signed, witnessed and paid for --- are being rejected by financial-services companies.
7:50 a.m. Sept. 9, 2021 - By Nicole Lyn Pesce
Sen. Amy Klobuchar urges Americans to get health checkups after revealing she had breast cancerMore than 1 in 3 adults has delayed health care during the pandemic
12:59 a.m. Sept. 7, 2021 - MarketWatch.com
10 ways to improve your health and live longerThere are some astonishing new technologies on the horizon that will help you to 'grow young.' Why not be around to experience some of them?
10:03 a.m. Sept. 6, 2021 - Barrons.com
5 Biotech Stocks That Could Lead a Revival The breakout success of Moderna and the rich premiums being paid for biotech M&A targets point to the substantial value that is hiding among the sector’s dross.
5:33 a.m. Sept. 2, 2021 - By Barbara Kollmeyer
Robinhood investors are propping up this stock market, says JPMorganOur call of the day from JPMorgan, says aggress offers up a fresh view on the chances of a correction for stocks
2:31 p.m. Sept. 1, 2021 - Barrons.com
Judge Approves Purdue Pharma Bankruptcy Plan That Frees Sacklers From Lawsuits Here's what you need to know to navigate the markets today.
2:03 a.m. Aug. 31, 2021 - By Paul Brandus
Eyes, ears, teeth: Big changes coming -- maybe -- to MedicareHealthy teeth and gums are gatekeepers to the rest of your body
7:14 a.m. Aug. 30, 2021 - Barrons.com
Biogen Is Giving Away Its Controversial Alzheimer's Drug: Report Aduhelm costs $56,000 a year and some insurers have been slow to make reimbursements, Reuters reported. Doctors also are questioning the drug's effectiveness.
12:52 p.m. Aug. 27, 2021 - By Christine Idzelis
S&P 500, Nasdaq end at all-time highs as U.S. stocks book weekly gains after Powell's dovish Jackson Hole speechU.S. stocks close higher Friday to book weekly gains, with the S&P 500 and Nasdaq Composite indexes finishing at fresh peaks, following Federal Reserve Chair Jerome Powell's remarks at the Jackson Hole central bankers' symposium.
12:26 p.m. Aug. 27, 2021 - By Tomi Kilgore
Cassava Sciences punches back, after Qaunterix took a swing by saying it didn’t interpret or prepare the disputed trial dataQuanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of the trial data that have been disputed.
4:58 a.m. Aug. 27, 2021 - By Tomi Kilgore
Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under disputeQuanterix Corp. said that while it was previously engaged by Cassava Sciences Inc. to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because of , Cassava had said that data from Alzheimer's patients were generated by Quanterix. The news of the halt request had sent Cassava's stock plunging 39.9% in two days through Thursday. Quanterix's stock dropped 9.2% on Thursday, after losing 1.5% on Wednesday. In Friday's statement, Quanterix said it is "widely recognized for its commitment to business integrity and to upholding the highest standards of quality." Quanterix's stock rose 4.5% in premarket trading, while Cassava shares tumbled 21.2%
7:48 a.m. Aug. 26, 2021 - Barrons.com
Early Sales of Biogen's Alzheimer Drug Remain Unclear Insight into the state of the uptake is turning muddier after two analysts published back-to-back research notes painting different pictures of how early sales are progressing.
2:00 a.m. Aug. 26, 2021 - Barrons.com
Not Your Traditional Value Fund The Cambiar Opportunity fund looks for well-managed, intellectual-property-driven businesses whose stocks offer good value.
12:33 p.m. Aug. 25, 2021 - By Joy Wiltermuth
S&P 500, Nasdaq Composite extend record run as Dow posts 4th straight day of gainsU.S. stock indexes close further in record territory Wednesday, as Congress eyes more fiscal stimulus and strong second-quarter corporate earnings help offset doubts about the pace of economic recovery.
2:37 a.m. Aug. 25, 2021 - By Tomi Kilgore
Cassava Sciences stock tumbles, and company responds to allegations disputing trial dataCassava Sciences Inc. responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients. The stock then tumbled after the bell -- it was down 17.8% in Wednesday's premarket -- after requesting the FDA halt the current clinical studies of simufilam, disputing the validity of clinical biomarker data, the integrity of western blot analyses and the integrity of analyses involving human brain tissue. "As a science company, we champion facts that can be evaluated and verified," said Chief Executive Remi Barbier. "This helps people make informed choices. It is important for stakeholders to separate fact from fiction, which is why we wish to address allegations head-on." Cassava with the "fact" that data from Alzheimer's patients were generated by an independent company, Quanterix Corp., and said western blot analysis is "foundational," and a standard lab technique used to detect a protein of interest. The stock has rocketed 1,627.7% year to date through Tuesday, while the S&P 500 has gained 19.4%.
3:00 a.m. Aug. 23, 2021 - Barrons.com
A Top U.S. Pension Manager Bought Up Philip Morris Stock Tennessee’s state pension manager bulked up its stake in tobacco giant Philip Morris. It slashed stakes in GE, Eli Lilly, and Baker Hughes stock.
2:58 a.m. Aug. 17, 2021 - By Tonya Garcia
Eli Lilly creates neuroscience and immunology business unitsEli Lilly & Co. announced Tuesday that it will split its Lilly Bio-Medicines division into two business units: Lilly Neuroscience and Lilly Immunology, effective September 5. Lilly Neuroscience will be led by Anne White, currently president of Lilly Oncology, now responsible for launched products and the unit's phase 3 portfolio in pain and neurodegeneration, including the potential launch of an Alzheimer's drug, donanemab. Loxo Oncology at Lilly Chief Executive Jacob Van Naarden will now add president of Lilly Oncology, bringing these business units together. Patrik Jonsson will be president of Lilly Immunology, leading launched products and the phase 3 portfolio in dermatology, gastroenterology and rheumatology in addition to serving as president of Lilly USA and chief customer officer. And Lilly International President Alfonso Zulueta will retire at the end of 2021 after more than 30 years. Ilya Yuffa, president of Lilly Bio-Medicines, will assume that role for all markets outside of the U.S. except for Canada. Eli Lilly shares have soared nearly 60% in 2021 while the benchmark S&P 500index has gained 19.3% for the period.
9:57 a.m. Aug. 14, 2021 - MarketWatch.com
How to rein in pricey prescription costs on MedicareIf you’re facing high prescription costs on Medicare, there are strategies that can help you lower the tab. Here are a few things to try.
11:12 a.m. Aug. 11, 2021 - MarketWatch.com
Will COVID-19 have long-term effects on the brain?A roundup of the latest news in dementia research: A rise in younger-onset dementia, the impact of lockdowns, plus other news from a recent conference.
5:53 a.m. Aug. 11, 2021 - Barrons.com
The FDA Rejects FibroGen Drug. The Damage to the Stock Is Already Done. The long-expected rejection of FibroGen’s application for approval of its drug roxadustat finally arrived early Wednesday morning.
10:29 a.m. Aug. 7, 2021 - By Brett Arends
Meet the retirees with the memory of a 25-year oldWouldn’t it be great if our brains didn’t decline?
10:00 a.m. Aug. 6, 2021 - By Alessandra Malito
News and analysis for those planning for or living in retirementRetirement news and analysis
6:35 a.m. Aug. 4, 2021 - By Howard Gold
Dementia and Alzheimer’s disease: How to spot -- and prevent -- themWatch for the signs and cultivate healthy habits to keep your memory intact
9:28 a.m. Aug. 3, 2021 - Barrons.com
Eli Lilly Stock Is Soaring. Sales Bounced Back. Drug giant Eli Lilly's second-quarter sales grew 12%, after adjusting for Covid-19's impact, while earnings matched Wall Street forecasts.
2:00 a.m. Aug. 1, 2021 - Barrons.com
A Huge Pension Bet Big on Moderna Stock. It Sold Starbucks, United, and Eli Lilly. State Teachers Retirement System of Ohio loaded up on Moderna stock in the second quarter, and lowered investments in Starbucks, United Airlines, and Eli Lilly.
10:00 a.m. July 30, 2021 - By Alessandra Malito
News and analysis for those planning for or living in retirementRetirement news and analysis
8:17 a.m. July 29, 2021 - By Quentin Fottrell
My mother was diagnosed with Alzheimer’s. My siblings created chaos in her life. Should I help my mom change her will?‘After suffering elder abuse by two siblings, she moved in with me a year ago, and is now under professional guardianship/conservatorship.’
6:08 a.m. July 28, 2021 - Barrons.com
Bristol Myers Squibb Stock Rises After Modest Earnings Beat Shares of Bristol Myers Squibb rose early Wednesday, after the company reported earnings that just beat Wall Street expectations.
3:04 a.m. July 28, 2021 - By Brett Arends
The latest Alzheimer's risk? CoffeeShould you give up your morning Joe? It depends
8:15 a.m. July 23, 2021 - By Jaimy Lee
Biogen, under pressure, tells investors it 'stands by' the FDA review process for its Alzheimer's drugBiogen executives sought to assure investors that the science behind its newly approved Alzheimer’s disease drug is firm despite ongoing questions about whether the drug works, how it was approved, and what it costs.
12:27 p.m. July 22, 2021 - By William Watts
U.S. stocks book 3rd day of gains, despite rise in jobless claims, as investors focus on earningsU.S. stocks closed higher Thursday for a third straight day, despite earlier data showing first-time applications for unemployment benefits rose last week.
10:11 a.m. July 22, 2021 - By Jaimy Lee
Biogen beats on earnings, says it's brought in $2 million in sales of Alzheimer's drugShares of Biogen gained 1.6% in premarket trading on Thursday after the company beat expectations for the second quarter and disclosed that it's already sold $2 million of its new, controversial Alzheimer's disease drug. Biogen had earnings of $448.5 million, or $2.99 per share, in the second quarter of 2021, compared to $1.5 billion, or $9.59 per share, in the same quarter a year ago. Adjusted EPS were $5.68, against a FactSet consensus of $4.55. Revenue was $2.7 billion for the quarter, down from $3.7 billion in the second quarter of 2020. The FactSet consensus was $2.6 billion. Biogen cited a 24% decline of revenue in its multiple sclerosis portfolio for the quarter; Tecfidera sales, for example, tumbled to $578.5 million for the quarter, compared with $1.19 billion in the same quarter a year ago. Biogen said its recently approved Alzheimer's drug Aduhelm brought in $2 million in revenue during the quarter even as questions persist about the . The company updated its guidance for the year, now saying it expects revenue of $10.65 billion to $10.85 billion, instead of $10.45 billion to $10.75 billion. Biogen's stock is up 31.9% so far this year, while the broader S&P 500 is up 15.1%.
7:03 a.m. July 22, 2021 - Barrons.com
Biogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong. The figure was below the $6.3 million analysts surveyed by FactSet expected, but the gap is relatively small for a drug expected to bring in billions.
6:19 a.m. July 19, 2021 - Barrons.com
Biogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says Piper Sandler's Christopher Raymond argues that many neurologists still plan to prescribe Aduhelm and that insurers would largely cover the therapy's cost.
4:00 p.m. July 16, 2021 - Barrons.com
Meme Stocks: The Risks and Rewards Letters on the meme-stock phenomenon, Alzheimer’s and the FDA, and Malibu Boats.
3:30 p.m. July 16, 2021 - Barrons.com
Why Biohaven Pharma’s Prospects Look Healthy Migraine drug posts strong sales, and investors might be underestimating value of the company’s coming product pipeline. Also, Wall Street opinions on Netflix, Nova Measuring Instruments, TPI Composites, and Whole Earth Brands.
6:24 a.m. July 16, 2021 - By Eleanor Laise
Drug-company-paid user fees under the microscope with beleaguered FDA in funding talksFees paid by drug and device makers influence agency operations at the expense of patient safety, critics say.
Browse topics:
Link to MarketWatch's Slice.